Eloxx Pharmaceuticals
ELOX
22 hedge funds and large institutions have $34.7M invested in Eloxx Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
63.8% more ownership
Funds ownership: 0% → 63.8% (+64%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$5.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.1M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.1M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$5.1M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$5.1M |
Top Sellers
ELOX Hedge Fund Activity: Q2 2026 in Review
22 of the 8,336 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals (ELOX) for Q2 2026, worth a combined $34.7M.
Buyers outnumbered sellers: 22 funds opened new ELOX positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Aberdeen Group, opening a new position worth an estimated $5.1M.
- 22 institutional investors held Eloxx Pharmaceuticals (ELOX) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $34.7M of Eloxx Pharmaceuticals stock for Q2 2026.
- 22 funds opened new Eloxx Pharmaceuticals positions in Q2 2026 and 0 closed out, a net change of +22 holders.
- The largest Eloxx Pharmaceuticals buyer in Q2 2026 was Aberdeen Group, an estimated $5.1M added.
Based on aggregated 13F filings for Q2 2026.